The UK and US have signed a important trade agreement that will preserve zero levies on UK drug shipments being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on medicines through the public health system. This commitment secures that duties on these key goods will be held at nothing for a timeframe of three years.
This deal comes after recent threats to dramatically increase duties on branded drug imports, with figures floated up to 100%.
"This arrangement with the Britain bolsters the global environment for new treatments and establishes much-needed balance to transatlantic drug exports," a release noted.
Trade Impact
Drugs are one of the UK's largest goods shipped to the America, which is by far the largest market for leading UK drugmakers.
Trade data show that in the one-year period to the end of last September, the UK exported medicines totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This agreement safeguards work, boosts investment and paves the way for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal includes several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, refunds topped twenty percent.
Industry Background
The pact follows a protracted dispute between the sector and the UK government over spending levels and regulatory access.
These tensions were heightened by claims that US customers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.
